Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512454 · ClinicalTrials.gov registry record
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
A clinical trial of Alpha1-Antitrypsin Deficiency, sponsored by Takeda.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT06512454 is a study of Alpha1-Antitrypsin Deficiency that is actively recruiting participants, run by Takeda. The registered enrollment target is 500 participants, above the 60-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (733% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06512454, a study of Alpha1-Antitrypsin Deficiency, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main aim of this study is to learn about liver problems caused by the lack of alpha-1 antitrypsin (called Alpha-1 Antitrypsin Deficiency or AATD) in adults when not treated (this is called the natural history of a condition) over 5 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagnosed and watched in normal hospital care, and describe how the AATD also affects and adult's lung function. Data in this study will be collected to include medical history of a participant, including the date AATD was first identified and/or the date on which the first AATD-related liver or lung problems were diagnosed. At study start and then every year until study end, participants will be asked to completed questionnaires (called patient-reported outcomes or PRO).
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (2)
Florida
- University of Florida - Gainesville
North Rhine-Westphalia
- Universitätsklinikum Aachen AöR - Aachen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2032-04-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512454
The ClinicalTrials.gov registry entry for NCT06512454 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 60-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (733% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha1-Antitrypsin Deficiency appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06512454 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT06512454 about?
NCT06512454 is a clinical study titled "A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems". The main aim of this study is to learn about liver problems caused by the lack of alpha-1 antitrypsin (called Alpha-1 Antitrypsin Deficiency or AATD) in adults when not treated (this is called the natural history of a condition) over 5 years. Other aims are to learn what can predict the AATD-liver c...
What is the current status of trial NCT06512454?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-09-25. Estimated completion is 2032-04-06.
What conditions does trial NCT06512454 study?
This clinical trial studies the following conditions: Alpha1-Antitrypsin Deficiency.
What interventions are being tested in trial NCT06512454?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06512454?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512454 being conducted?
This trial has 2 study locations across Florida, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha1-Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RECRUITING · Phase 3
-
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RECRUITING · Phase 3
-
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
COMPLETED · Phase 1
-
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.